Aclaris Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
20 Setembro 2023 - 8:00AM
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage
biopharmaceutical company focused on developing novel drug
candidates for immuno-inflammatory diseases, today announced that
members of the Aclaris management team will participate in a
fireside chat during the 2023 Cantor Global Healthcare Conference
on Tuesday, September 26, 2023 at 10:30 AM ET, in New York, NY.
A webcast of the fireside chat may be accessed through the
“Events” page of the “Investors” section of Aclaris’ website,
www.aclaristx.com. The webcast will be archived for at least 30
days on the Aclaris website.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical
company developing a pipeline of novel drug candidates to address
the needs of patients with immuno-inflammatory diseases who lack
satisfactory treatment options. The company has a multi-stage
portfolio of drug candidates powered by a robust R&D engine
exploring protein kinase regulation. For additional information,
please visit www.aclaristx.com.
Aclaris Therapeutics Contact:
Robert A. Doody Jr.Vice President, Investor
Relations484-639-7235rdoody@aclaristx.com
Aclaris Therapeutics (NASDAQ:ACRS)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Aclaris Therapeutics (NASDAQ:ACRS)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024